Biology Reference
In-Depth Information
Hermann R, Lahu G, Hauns B, Bethke T, Zech K (2006b) Total PDE4 inhibitory activity: a
concept for evaluating pharmacokinetic alterations of roflumilast and roflumilast N-oxide in
special populations and drug-drug interactions (abstract). Eur Respir J 28:436s
Hermann R, Nassr N, Lahu G, P´terfai E, Knoerzer D, Herzog R, Zech K, de Mey C (2007a)
Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and
moderate liver cirrhosis. Clin Pharmacokinet 46:403-416
Hermann R, Siegmund W, Giessmann T, Westphal K, Weinbrenner A, Hauns B, Reutter F,
Lahu G, Zech K, Bethke TD (2007b) The oral, once-daily phosphodiesterase 4 inhibitor
roflumilast lacks relevant pharmacokinetic interactions with inhaled budesonide. J Clin
Pharmacol 47:1005-1013
Hogg JC, Timens W (2009) The pathology of chronic obstructive pulmonary disease. Annu Rev
Pathol 4:435-459
Hohlfeld JM, Schoenfeld K, Lavae-Mohktari M, Schaumann F, Mueller F, Bredenbroeker D, Krug
N, Hermann R (2008) Roflumilast attenuates pulmonary inflammation upon segmental endo-
toxin challenge in healthy subjects: a randomiszed placebo-controlled trial. Pulm Pharmacol
Ther 21:616-623
Horowski R, Sastre-Y-Hernandez M (1985) Clinical effects of the neurotrophic selective
cAMP phosphodiesterase inhibitor rolipram in depressed patients: global evaluation of the
preliminary reports. Curr Ther Res 38:23-29
Huang Z, Liu S, Zhang L, Salem M, Greig GM, Chan CC, Natsumeda Y, Noguchi K (2006)
Preferential inhibition if human phosphodiesterase 4 by ibudilast. Life Sci 78:2663-2668
Inoue N, Harada M (2008) Effect of ibudilast on non-specific symptoms in patients with chronic
cerebral ischemia. Analysis of cerebral blood flow. Arzneimittelforschung 58:277-282
Kawasaki A, Hoshino K, Osaki R, Mizushima Y, Yano S (1992) Effect of ibudilast: a novel
antiasthmatic agent, on airway hypersensitivity in bronchial asthma. J Asthma 29:245-252
Kelly J, Murdoch RD, Clark DJ, Zussman B, Davie C, Howland K (1999) Smoking status
has no effect on the clearance of a single dose of Ariflo (SB207499) (15mg), an orally active,
novel, second generation PDE4 inhibitor in healthy male volunteers. Am J Respir Crit Care
Med 159:A807
Kelly J, Murdoch RD, Clark DJ, Webber DM, Fuder H (2001) Warfarin pharmacodynamics
unaffected by cilomilast. Ann Pharmacother 35:1535-1539
Keshavarzian A, Mutlu E, Guzman P, Forsyth C, Banan A (2007) Phosphodiesterase 4 inhibitors
and inflammatory bowel disease: emerging therapies in inflammatory bowel disease. Expert
Opin Investig Drugs 16:1489-1506
Knowles RG, Tralau-Stewart C, Dawson J et al (2009) In vitro characterization of GSK256066, an
exceptionally high affinity and selective inhibitor of PDE4 suitable for topical administration.
Am J Respir Crit Care Med 179:A4581
Krause W, Kuhne G (1993) Biotransformation of the antidepressant D, L-rolipram. II. Metabolite
patterns in man, rat, rabbit, rhesus and cynomolgus monkey. Xenobiotica 23:1277-1288
Krause W, Kuhne G, Matthes H (1989) Pharmacokinetics of the antidepressant rolipram in healthy
volunteers. Xenobiotica 19:683-692
Krause W, Kuhne G, Sauerbrey N (1990) Pharmacokinetics of (+)-rolipram and (-)-rolipram in
healthy volunteers. Eur J Clin Pharmacol 38:71-75
Kuss H, Hoefgen N, Johanssen S, Kronbach T, Rundfeldt C (2003) In vivo efficacy in airway
disease models of N-(3, 5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-
glyoxylic acid amide (AWD12-281), a selective PDE4 inhibitor for inhaled administration.
J Pharmacol Exp Ther 307:373-385
Laazar AL, Mistry S, Barrett C, Lulic-Burns Z (2010) A four-week randomized study of the safety
and tolerability of the inhaled PDE4 inhibitor GSK256066 in COPD. Am J Respir Crit Care
Med 181:A4444 (abstract)
Lahu G, Huennemeyer A, von Richter O, Hermann R, Herzog R, McCracken N, Zech K (2008)
Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and
roflumilast N-oxide. J Clin Pharmacol 48:1339-1349
